Pharmaceutical care in Alzheimer's Disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/21247 |
Resumo: | Alzheimer's Disease (AD) is a neurodegenerative disorder and the main cause of dementia, as the disease initially affects the hippocampus and slowly progresses to other parts of the brain, causing cell damage and death, specifically of neurons, generating irreversible damage and consequences for all cognitive functioning. , affective, intellectual and behavioral, negatively influencing the individual's autonomy and independence. Patients are undergoing treatments for chronic use, as there is no cure for Alzheimer's disease. Treatment aims to minimize the symptoms of the disease, enabling partial improvement to prolong survival and delay progression. Given the real importance of pharmaceutical assistance directed to the patient, which optimizes the response of a given pharmacotherapy, through which the pharmacist, together with the patient, carries out a follow-up plan. In this context, this work aims to highlight the importance of pharmaceutical care both in pharmacotherapy and outside it. This is a cross-sectional and descriptive integrative review study with a qualitative and quantitative approach on the subject, where searches were made in the Scielo and VHL databases about the subject. A total of 1,199 works were found, in which a screening was carried out to collect the results. It was observed that the treatment of Alzheimer's Disease is capable of delaying or temporarily stagnating the advance of symptoms, aiming to alleviate cognitive deficits, behavioral changes and improve the quality of life of the patient and his family. The treatment of Alzheimer's Disease must be multidisciplinary and with the objective of providing stabilization of cognitive impairment, modifying the manifestations of the disease, with a minimum of adverse effects. In this context, immunomodulators are more likely to become drugs capable of influencing the course of AD, as the selected studies had better quality and the results were promising. On the other hand, the toxicity of drugs for the treatment of AD is a major obstacle, and to overcome this situation, the presence of pharmaceutical care becomes increasingly essential. |
id |
UNIFEI_5afbc1650d094f2b61add455ff77ab2b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/21247 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Pharmaceutical care in Alzheimer's DiseaseAtención farmacéutica en la Enfermedad de AlzheimerAtenção farmacêutica na Doença de AlzheimerEnfermedad de AlzheimerEnfermedad de Alzheimer. Atención farmacéutica. Anciano.Atención farmacéuticaAnciano.Doença de Alzheimer. Atenção Farmacêutica. Idoso.Doença de AlzheimerAtenção FarmacêuticaIdoso.Alzheimer's DiseasePharmaceutical attentionOld man.Alzheimer's Disease (AD) is a neurodegenerative disorder and the main cause of dementia, as the disease initially affects the hippocampus and slowly progresses to other parts of the brain, causing cell damage and death, specifically of neurons, generating irreversible damage and consequences for all cognitive functioning. , affective, intellectual and behavioral, negatively influencing the individual's autonomy and independence. Patients are undergoing treatments for chronic use, as there is no cure for Alzheimer's disease. Treatment aims to minimize the symptoms of the disease, enabling partial improvement to prolong survival and delay progression. Given the real importance of pharmaceutical assistance directed to the patient, which optimizes the response of a given pharmacotherapy, through which the pharmacist, together with the patient, carries out a follow-up plan. In this context, this work aims to highlight the importance of pharmaceutical care both in pharmacotherapy and outside it. This is a cross-sectional and descriptive integrative review study with a qualitative and quantitative approach on the subject, where searches were made in the Scielo and VHL databases about the subject. A total of 1,199 works were found, in which a screening was carried out to collect the results. It was observed that the treatment of Alzheimer's Disease is capable of delaying or temporarily stagnating the advance of symptoms, aiming to alleviate cognitive deficits, behavioral changes and improve the quality of life of the patient and his family. The treatment of Alzheimer's Disease must be multidisciplinary and with the objective of providing stabilization of cognitive impairment, modifying the manifestations of the disease, with a minimum of adverse effects. In this context, immunomodulators are more likely to become drugs capable of influencing the course of AD, as the selected studies had better quality and the results were promising. On the other hand, the toxicity of drugs for the treatment of AD is a major obstacle, and to overcome this situation, the presence of pharmaceutical care becomes increasingly essential.La Enfermedad de Alzheimer (EA) es un trastorno neurodegenerativo y la principal causa de demencia, ya que la enfermedad afecta inicialmente al hipocampo y progresa lentamente a otras partes del cerebro, provocando daño celular y muerte, específicamente de neuronas, generando daños y consecuencias irreversibles para todo el funcionamiento cognitivo. , afectiva, intelectual y conductual, influyendo negativamente en la autonomía e independencia del individuo. Los pacientes se someten a tratamientos de uso crónico, ya que no existe cura para la enfermedad de Alzheimer. El tratamiento tiene como objetivo minimizar los síntomas de la enfermedad, permitiendo una mejoría parcial para prolongar la supervivencia y retrasar la progresión. Dada la importancia real de la asistencia farmacéutica dirigida al paciente, que optimiza la respuesta de una determinada farmacoterapia, mediante la cual el farmacéutico, junto con el paciente, realiza un plan de seguimiento. En este contexto, este trabajo tiene como objetivo resaltar la importancia de la atención farmacéutica tanto en la farmacoterapia como fuera de ella. Se trata de un estudio de revisión transversal, descriptivo, integrador, con abordaje cualitativo y cuantitativo sobre el tema, donde se realizaron búsquedas en las bases de datos Scielo y BVS sobre el tema. Se encontraron un total de 1.199 trabajos, en los que se realizó un cribado para recoger los resultados. Se observó que el tratamiento de la Enfermedad de Alzheimer es capaz de retrasar o estancar temporalmente el avance de los síntomas, con el objetivo de paliar déficits cognitivos, cambios de comportamiento y mejorar la calidad de vida del paciente y su familia. El tratamiento de la Enfermedad de Alzheimer debe ser multidisciplinar y con el objetivo de proporcionar la estabilización del deterioro cognitivo, modificando las manifestaciones de la enfermedad, con un mínimo de efectos adversos. En este contexto, es más probable que los inmunomoduladores se conviertan en fármacos capaces de influir en el curso de la EA, ya que los estudios seleccionados tuvieron mejor calidad y los resultados fueron prometedores. Por otro lado, la toxicidad de los fármacos para el tratamiento de la EA es un gran obstáculo, y para superar esta situación, la presencia de cuidados farmacéuticos se vuelve cada vez más imprescindible.A Doença de Alzheimer (DA) é um distúrbio neurodegenerativo e principal causa de demência, pois a doença afeta inicialmente o hipocampo e progride lentamente para outras partes do cérebro, causando dano celular e morte, especificamente de neurônios, gerando danos irreversíveis e consequências para todo o funcionamento cognitivo, afetiva, intelectual e comportamental, influenciando negativamente na autonomia e independência do indivíduo. Os pacientes são submetidos a tratamentos de uso crônico, visto que não há cura para a doença de Alzheimer. O tratamento visa minimizar os sintomas da doença, possibilitando melhora parcial para prolongar a sobrevida e retardar a progressão. Dada a real importância da assistência farmacêutica dirigida ao paciente, que otimiza a resposta de uma determinada farmacoterapia, por meio da qual o farmacêutico juntamente com o paciente, realiza um plano de acompanhamento. Nesse contexto, este trabalho tem como objetivo salientar a importância da atenção farmacêutica tanto na farmacoterapia quanto fora da mesma. Trata-se de um estudo de revisão integrativa transversal e descritiva com abordagem qualitativa e quantitativa sobre o tema, onde foram feitas buscas nas bases de dados Scielo e BVS acerca do tema. Foram encontrados 1.199 trabalhos, no qual foi feita uma triagem para a coleta dos resultados. Foi observado que o tratamento da Doença de Alzheimer é capaz de retardar ou estagnar, temporariamente, o avanço dos sintomas visando aliviar os déficits cognitivos, as alterações de comportamento e melhorar a qualidade de vida do portador e de sua família. O tratamento da Doença de Alzheimer deve ser multidisciplinar e com o objetivo de propiciar a estabilização do comprometimento cognitivo, modificando as manifestações da doença, com um mínimo de efeitos adversos. Nesse contexto, os imunomoduladores têm maior probabilidade de se tornarem drogas capazes de influenciar o curso da DA, pois os estudos selecionados apresentaram melhor qualidade e os resultados foram promissores. Por outro lado, a toxicidade das drogas para o tratamento da DA constitui um grande obstáculo, e para contornar tal situação a presença da atenção farmacêutica se torna cada vez mais imprescindível.Research, Society and Development2021-10-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2124710.33448/rsd-v10i13.21247Research, Society and Development; Vol. 10 No. 13; e385101321247Research, Society and Development; Vol. 10 Núm. 13; e385101321247Research, Society and Development; v. 10 n. 13; e3851013212472525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/21247/19027Copyright (c) 2021 Patricia Rayanne; Lenara Veras; Joseana Martins Soares de Rodrigues Leitãohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRayanne, PatriciaVeras, LenaraLeitão, Joseana Martins Soares de Rodrigues2021-11-21T18:26:28Zoai:ojs.pkp.sfu.ca:article/21247Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:40:42.603648Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Pharmaceutical care in Alzheimer's Disease Atención farmacéutica en la Enfermedad de Alzheimer Atenção farmacêutica na Doença de Alzheimer |
title |
Pharmaceutical care in Alzheimer's Disease |
spellingShingle |
Pharmaceutical care in Alzheimer's Disease Rayanne, Patricia Enfermedad de Alzheimer Enfermedad de Alzheimer. Atención farmacéutica. Anciano. Atención farmacéutica Anciano. Doença de Alzheimer. Atenção Farmacêutica. Idoso. Doença de Alzheimer Atenção Farmacêutica Idoso. Alzheimer's Disease Pharmaceutical attention Old man. |
title_short |
Pharmaceutical care in Alzheimer's Disease |
title_full |
Pharmaceutical care in Alzheimer's Disease |
title_fullStr |
Pharmaceutical care in Alzheimer's Disease |
title_full_unstemmed |
Pharmaceutical care in Alzheimer's Disease |
title_sort |
Pharmaceutical care in Alzheimer's Disease |
author |
Rayanne, Patricia |
author_facet |
Rayanne, Patricia Veras, Lenara Leitão, Joseana Martins Soares de Rodrigues |
author_role |
author |
author2 |
Veras, Lenara Leitão, Joseana Martins Soares de Rodrigues |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Rayanne, Patricia Veras, Lenara Leitão, Joseana Martins Soares de Rodrigues |
dc.subject.por.fl_str_mv |
Enfermedad de Alzheimer Enfermedad de Alzheimer. Atención farmacéutica. Anciano. Atención farmacéutica Anciano. Doença de Alzheimer. Atenção Farmacêutica. Idoso. Doença de Alzheimer Atenção Farmacêutica Idoso. Alzheimer's Disease Pharmaceutical attention Old man. |
topic |
Enfermedad de Alzheimer Enfermedad de Alzheimer. Atención farmacéutica. Anciano. Atención farmacéutica Anciano. Doença de Alzheimer. Atenção Farmacêutica. Idoso. Doença de Alzheimer Atenção Farmacêutica Idoso. Alzheimer's Disease Pharmaceutical attention Old man. |
description |
Alzheimer's Disease (AD) is a neurodegenerative disorder and the main cause of dementia, as the disease initially affects the hippocampus and slowly progresses to other parts of the brain, causing cell damage and death, specifically of neurons, generating irreversible damage and consequences for all cognitive functioning. , affective, intellectual and behavioral, negatively influencing the individual's autonomy and independence. Patients are undergoing treatments for chronic use, as there is no cure for Alzheimer's disease. Treatment aims to minimize the symptoms of the disease, enabling partial improvement to prolong survival and delay progression. Given the real importance of pharmaceutical assistance directed to the patient, which optimizes the response of a given pharmacotherapy, through which the pharmacist, together with the patient, carries out a follow-up plan. In this context, this work aims to highlight the importance of pharmaceutical care both in pharmacotherapy and outside it. This is a cross-sectional and descriptive integrative review study with a qualitative and quantitative approach on the subject, where searches were made in the Scielo and VHL databases about the subject. A total of 1,199 works were found, in which a screening was carried out to collect the results. It was observed that the treatment of Alzheimer's Disease is capable of delaying or temporarily stagnating the advance of symptoms, aiming to alleviate cognitive deficits, behavioral changes and improve the quality of life of the patient and his family. The treatment of Alzheimer's Disease must be multidisciplinary and with the objective of providing stabilization of cognitive impairment, modifying the manifestations of the disease, with a minimum of adverse effects. In this context, immunomodulators are more likely to become drugs capable of influencing the course of AD, as the selected studies had better quality and the results were promising. On the other hand, the toxicity of drugs for the treatment of AD is a major obstacle, and to overcome this situation, the presence of pharmaceutical care becomes increasingly essential. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-10-17 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/21247 10.33448/rsd-v10i13.21247 |
url |
https://rsdjournal.org/index.php/rsd/article/view/21247 |
identifier_str_mv |
10.33448/rsd-v10i13.21247 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/21247/19027 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Patricia Rayanne; Lenara Veras; Joseana Martins Soares de Rodrigues Leitão https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Patricia Rayanne; Lenara Veras; Joseana Martins Soares de Rodrigues Leitão https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 13; e385101321247 Research, Society and Development; Vol. 10 Núm. 13; e385101321247 Research, Society and Development; v. 10 n. 13; e385101321247 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052692043923456 |